Expanded Access Policy

Expanded access, also called “compassionate use”, is a potential pathway for patients with serious or immediately life-threatening conditions to get access to investigational medical product for treatment outside of clinical trials when no comparable or satisfactory alternative therapies are available.​

Adcendo’s product programs currently include investigational drugs that have not received marketing approval from the FDA, EMA, or any other regulatory agency. The investigational drugs may, or may not, be effective and their use may cause unexpected serious side effects. ​

Currently, Adcendo does not have an expanded access available for any of our investigational drugs.

Presently, participation in one of our clinical trials is the only way to access Adcendo’s investigational drugs. We encourage patients and healthcare providers interested in our investigational drugs to explore details about our ongoing studies on clinicaltrials.gov and our website.​